Biomarkers for Ventilator-associated Pneumonia

Recruiting now

Conditions studied: Pneumonia, Ventilator-Associated

In brief

The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.

Key facts

Study ID

NCT05117125

Run by

Region Skane

People needed

1000

Starts

2021-10-15

Expected to finish

2028-12-31

Last updated by the study team

2026-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Admission to an intensive care unit
• Intubation within last 24 hours
• Anticipated mechanical ventilation of at least 48 hours

You may not qualify if…

• FiO2 above 70% or PEEP above 15
• Severe coagulopathy (spontaneous PK(INR) >1.8 or thrombocytes <50). Prophylaxis treatment dose of LMWH or factor Xa inhibitors/NOAC is not an exclusion criteria. If higher doses of these substances are administered, the responsible clinician should be consulted before sample collection.
• Ongoing infection of the lungs at admission to the ICU.
• Severely elevated or instable intracranial pressure.

Where it is running

• Vestre Viken — Drammen, Norway (enrolling)
• Hospital de São Francisco Xavier — Lisbon, Portugal (enrolling)
• Skåne University Hospital, Dept. of Infectious diseases — Lund, Sweden (enrolling)
• Skåne university Hospital, ICU — Malmö, Sweden (enrolling)
• Karolinska University Hospital, ICU — Solna, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.